We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays
Product News

LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays

LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays
Product News

LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "LabCorp® Announces the Availability of Affymetrix-Based Whole Genome Microarrays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Laboratory Corporation of America® Holdings (LabCorp®) has announced the availability of an ultra high-density microarray, Affymetrix based technology (Whole-Genome Sampling Analysis). The offering continues the numerous recent advances in LabCorp’s clinical genetics laboratory diagnostics.

In 2005, LabCorp first offered the comparative genomic hybridization (CGH) based microarray diagnostics which focused on mental retardation and developmental delay. This targeted testing underscored the need for higher density whole genome coverage.

The Affymetrix-based technology provides analysis of DNA copy number changes – identifying deletions, gene amplifications and loss of heterozygosity (LOH).

“This new testing will offer unparalleled resolution for the detection of the etiology of mental retardation, developmental delay, autism and other clinically significant changes and underscores LabCorp’s commitment to providing physicians and patients the highest quality services to meet their clinical needs,” said Myla Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.

Advertisement